Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Dr.Ji has said Sorrento's DAR-T is 10-100 times as effective as CAR-T. For those following the science, someone posted....
"This:
https://www.prnewswire.com/news-releases/global-car-t-therapy-pipeline-market-analysis-report-2021-2030-featuring-novartis-kite-pharma-pfizer-juno-therapeutics-celgene-carsgen-therapeutics-sorrento-therapeutics-and-legend-biotech-301289750.html

is a recent market analysis of the CAR-T therapy market up to 2030. It mentions Sorrento as one of the leaders of this multi billion market.

First, it's pretty telling that the report itself is for sale for U$5000. So, if the report is that valuable, we can get an idea of the value of this market moving forward.

In Sorrento's pipeline we find this technology presently in the CD38 products, currently in phase 1 trials scheduled to end between Dec 21 and Feb 22.

Sorrento is also developing an even more advanced technology. In SRNE site it states:
" Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus.
The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv used by traditional Chimeric Antigen Receptor (CAR) T cells. We believe this DAR has been demonstrated in preclinical studies greater specificity, stability and potency.”
Let’s “translate” this so everyone can understand what it actually means and why Sorrento’s future is bright.

“Translation”:
SRNE uses a technology developed and owned by the company.

A gene of one organism is "knocked out" (made inoperative) and is substituted by a substitute gene, also known as a knock-in.

This technology uses a type of white blood cell called T cell, which are dominant cells in the part of the immune system that fights and eliminates pathogens, the organisms that can produce a disease. The T-cells used, originate from a blood donation of a healthy living person.

Those T-cells are then genetically engineered, essentially making a modification to their DNA. .

These T-cells are transformed into a dimer (a type of molecule) that then becomes the antigen-receptor. An antigen is more or less the outer layer of the pathogen, the disease-causing organism. The antigen is the part of the pathogen that our immune system can bind with, connect with, to neutralize or kill.

So here, through genetic engineering, we take a cell that has this immune system abilities, modify it so that it can connect with the specific intruder and kill or stop it, and to do so, we are able to transform this T-cell into a molecule that has the characteristics of a dimer (therefore it's a dimeric antigen receptor).

Of course it isn't that simple, actually this modified t-cell becomes part of a protein chain, the alpha chain, related to our blood cell antibodies. In fact, it becomes part of a specific portion of the alpha chain, the constant region portion, that is known as the Fragment Antigen Binding chain (or a FAB).

The FAB, as you might guess, is related to the ability of binding, connecting, with the antigen (the intruder) and eliminating it.

So the regular TRAC (The T Cell Alpha Chain) is knocked out, in favor of a modified gene sequence that knocks the antigen into a "locus control region", basically, a "control room" that will take care of the antigen.

So, the Dimeric Antigen Receptor (DAR T, T stands for T-cell) technology used by SRNE is an enhancement, an improvement, of the next-generation therapy known as Chimeric Antigen Reception (CAR T). The difference is that the DAR is using a Dimer, (specific type of molecule) and Chimeric actually stands for the general application of bringing in a modified gene to help.

CAR T uses single chain variable fragments (scFV), basically a protein used by joining two separate genes, which, let's put it this way, had different codes to begin with.

The dimeric technology, so to speak, uses a molecule that is already formed by two molecules that naturally have the ability to react with another molecule.

Maybe because of this natural trait, the dimeric technology seems to give better, stronger and more stable results.

So Sorrento isn’t just one of the leaders of a new type of technology worth billions, it is already developing the next generation of this technology, using an idea that is exclusive to SRNE. If you are long, that translates to: Sorrento is ahead of the pack in using a technology that grows by the billions each year."